300529 Jafron Biomedical
- 27.58
- +0.04+0.15%
Jafron Biomedical News
Jianfan Biology (300529): The trend of optimizing internal and external ecology and improving management is expected to continue
Jianfan Biotech (300529): Business performance, Liu Dian, Huaming, innovation and promotion have stepped up
Jianfan Biotech (300529): 24Q1 performance improved drastically, fundamentals reversed, inflection point reached
Jianfan Biotech (300529): Channel inventory improved, performance resumed growth
Jianfan Biotech (300529): 1Q24's performance returned to rapid growth
Jianfan Biotech (300529): First-quarter results resumed high growth and domestic and foreign product development progressed smoothly
Jianfan Biology (300529): At the end of the journey of thorns, the road to prosperity can still be expected
Jianfan Biotech (300529): Launched the “Double Improvement of Quality and Return” Program, a domestic leader in blood perfusion to promote high-quality global development
Jianfan Biotech (300529): Q3 company operations improved month-on-month, and the effects of systemic reforms are beginning to show
Jianfan Biotech (300529): 3Q23 performance improved month-on-month
Jianfan Biology (300529): The critical blood sector bucked the trend and employee stock ownership plans showed determination
Jianfan Biotech (300529): The new shareholding plan, which will have a big impact on the epidemic in 2022, shows confidence in long-term growth
Jianfan Biology (300529): Critical care products and blood purification equipment are growing rapidly
Jianfan Biotech (300529): Short-term results released under pressure, employee shareholding highlights confidence in long-term development
Jianfan Biology (300529): Business continues to be rich and optimistic about the recovery of the hospital side in '23
Jianfan Biology (300529): Blood perfusion is expected to bottom out and equipment products will explode rapidly
Jianfan Biology (300529) Company Comment: Results for the second half of the year continued to be pressured, and the new dialyzer product was approved domestically
Jianfan Biology (300529): Renal and Liver Disease Business Has Been Affected by the Epidemic and Increased Investment in R&D
Jianfan Biotech (300529) 2022 Third Quarter Report Review: Q3 was greatly affected by the epidemic and its performance fell short of expectations
Jianfan Biotech (300529) 2022 Third Quarter Report Review: Revenue performance in the third quarter was under pressure and R&D investment continued to grow
Analysis
Price Target
No Data
